Save time and get answers to complex questions with AI chat
What are the liver enzyme requirements for starting terbinafineWhen does the apixaban patent expire?Fda livtencity approval letter march 23 2021 regulatory project managerWhen does the patent expire on ibranceAdefovir dipivoxil discount card
See the DrugPatentWatch profile for Hepsera
Hepsera (adefovir dipivoxil) is used to treat chronic hepatitis B, including cases where the virus is resistant to lamivudine. Adefovir can suppress hepatitis B virus (HBV) in patients with lamivudine-resistant disease because it targets HBV with a different antiviral activity than lamivudine.
Lamivudine-resistant HBV means the virus has developed mutations that reduce how well lamivudine can control viral replication. In that setting, clinicians often switch to a different antiviral agent (or add one with a non-overlapping resistance profile) to regain viral suppression.
Even when Hepsera is active against lamivudine-resistant HBV, treatment still needs monitoring. Antiviral response may vary by patient, and long-term therapy requires follow-up to check HBV viral load response and to monitor kidney safety, since adefovir can affect renal function.
Other Questions About Hepsera :